TriangleNCT04985604 · OUTCOME
Duration of Progression Free Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 23 months
What was measured
Progression free survival was defined as the interval from the date of the first dose to the first occurrence of radiographic disease progression based on RECIST 1.1 or RANO criteria or death due to any cause, whichever occurs earlier. Progression free survival was estimated using Kaplan-Meier method.
Analysis population: Efficacy Analysis Set comprises of all participants who received at least one dose of study drug and have measurable disease as determined by the Investigator at baseline.
Groups in this outcome
Melanoma Cohort
Adult participants (≥ 18 years) were administered Tovorafenib 600 mg orally (PO) once weekly (QW).
Tissue Agnostic Cohort
Adult participants (≥ 18 years) were administered Tovorafenib 600 mg PO QW.
| Group | Source count |
|---|---|
| Melanoma Cohort | 8 |
| Tissue Agnostic Cohort | 15 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Melanoma Cohort | 5.5 | Not reported | 1.8 | 12.5 | Not reported |
| Tissue Agnostic Cohort | 5.5 | Not reported | 1.7 | NA | The upper bound of the 95% confidence interval was not estimable due to insufficient number of participants with events at the tail of the Kaplan-Meier curve. |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1.8
- upper Limit
- 12.5
- value
- 5.5
- comment
- The upper bound of the 95% confidence interval was not estimable due to insufficient number of participants with events at the tail of the Kaplan-Meier curve.
- group Id
- OG001
- lower Limit
- 1.7
- upper Limit
- NA
- value
- 5.5
- denoms
- counts
- group Id
- OG000
- value
- 8
- group Id
- OG001
- value
- 15
- units
- Participants
- description
- Progression free survival was defined as the interval from the date of the first dose to the first occurrence of radiographic disease progression based on RECIST 1.1 or RANO criteria or death due to any cause, whichever occurs earlier. Progression free survival was estimated using Kaplan-Meier method.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Adult participants (≥ 18 years) were administered Tovorafenib 600 mg orally (PO) once weekly (QW).
- id
- OG000
- title
- Melanoma Cohort
- description
- Adult participants (≥ 18 years) were administered Tovorafenib 600 mg PO QW.
- id
- OG001
- title
- Tissue Agnostic Cohort
- param Type
- MEDIAN
- population Description
- Efficacy Analysis Set comprises of all participants who received at least one dose of study drug and have measurable disease as determined by the Investigator at baseline.
- reporting Status
- POSTED
- time Frame
- Up to 23 months
- title
- Duration of Progression Free Survival
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice